Identification and Biological Evaluation of Fisetin as a Novel DYRK1B Inhibitor in Ovarian Cancer with Apoptotic and Ferroptotic Effects
Drug Design, Development and Therapy · 2026-11 · Volume 20 · 1-21
DOI: 10.2147/dddt.s631685 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2026-11. Verfasst von Auslin Sam und 3 weiteren Autor:innen. Beteiligte Einrichtung: Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Apoptosis, Flavonols, Ovarian Neoplasms, Protein Serine-Threonine Kinases. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
- Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
- Ph.D. Program in Innovative Medical Technology Research and Development Industry, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
ORCID-Profile: Auslin Sam, Wei-Chun HuangFu
Zitieren
APA
Sam, A., Peng, C. H., Hsu, K. C., & HuangFu, W. C. (2026). Identification and Biological Evaluation of Fisetin as a Novel DYRK1B Inhibitor in Ovarian Cancer with Apoptotic and Ferroptotic Effects. Drug Design, Development and Therapy, Volume 20, 1-21. https://doi.org/10.2147/dddt.s631685
Vancouver
Sam A, Peng CH, Hsu KC, HuangFu WC. Identification and Biological Evaluation of Fisetin as a Novel DYRK1B Inhibitor in Ovarian Cancer with Apoptotic and Ferroptotic Effects. Drug Design, Development and Therapy. 2026;Volume 20:1-21. doi:10.2147/dddt.s631685
BibTeX
@article{Sam2026,
author = {Sam, Auslin and Peng, Chao-Hsiang and Hsu, Kai-Cheng and HuangFu, Wei-Chun},
title = {Identification and Biological Evaluation of Fisetin as a Novel DYRK1B Inhibitor in Ovarian Cancer with Apoptotic and Ferroptotic Effects},
journal = {Drug Design, Development and Therapy},
year = {2026},
volume = {Volume 20},
pages = {1--21},
doi = {10.2147/dddt.s631685}
}
EUVIMED